The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
2020 · Breast Cancer · 75 citations
https://doi.org/10.1007/s12282-020-01085-0
K
Kei Koizumi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
35
Papers
588
Citations
11
h-index
14
i10-index
Kei Koizumi is an academic researcher from Hamamatsu University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 11, co-authored 30 publications.
Papers by this author
worksThe Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
2023 · Breast Cancer · 53 citations
https://doi.org/10.1007/s12282-023-01505-x
DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability
2014 · BMC Cancer · 32 citations
https://doi.org/10.1186/1471-2407-14-466
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
2020 · Trials · 14 citations
https://doi.org/10.1186/s13063-020-04341-y
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
2020 · Trials · 10 citations
https://doi.org/10.1186/s13063-020-04408-w
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial
2025 · Journal of Clinical Oncology · 8 citations
https://doi.org/10.1200/jco-24-01888
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat